(image: Philips International B.V.)
Amsterdam, the Netherlands, Jul. 3 (Korea Bizwire) – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced shipment of its two-millionth AED (Automated External Defibrillator), which was delivered to a customer in Italy. This achievement marks a major milestone in almost 20 years of Philips innovation in cardiac resuscitation aimed at providing personalized therapy to victims of sudden cardiac arrest. Cardiac arrests can happen anywhere, at any time, and bystander intervention and treatment with an AED has been shown to triple the survival rate to 31.4 percent [1].
“We are very proud of the knowledge that Philips AEDs have helped to save lives every day for almost two decades,” said Arman Voskerchyan, Business Leader Therapeutic Care at Philips. “As we have reached the incredible milestone of shipping our two-millionth AED worldwide, we will continue to provide our customers with reliable, easy-to-use lifesaving solutions.”
Earlier this year, Philips and the American Heart Association announced a collaboration to increase sudden cardiac arrest survival rates in densely populated cities around the world. The Connected Pulse program leverages a unique end-to-end solution combining education programs to increase awareness of CPR (Cardiopulmonary Resuscitation), the use of publicly available AEDs, and new technologies to strengthen the ‘chain of survival’ from the moment an incident occurs to the patient reaching the hospital.
A pioneer in AED innovation
Philips’ HeartStart OnSite AED made the implementation of early AED programs in communities, schools and businesses much easier, while the Philips HeartStart Home AED remains the only AED available in the US for home use. Philips was also the first to introduce an AED for pediatric use, and was a pioneer in providing AEDs for use in airplanes. Today, Philips AEDs are available across the globe, on board major airlines, in Fortune 100 companies, and in the locker rooms of professional sports teams worldwide.
Philips recently announced that the US Food and Drug Administration (FDA) has approved the company’s premarket approval (PMA) application for its HeartStart OnSite AED [2] and HeartStart Home AED [3], and the relevant accessories, such as batteries and electrodes [4].
More information on Philips’ portfolio of AEDs and the two-millionth AED milestone is available here.
[1] Response to Cardiac Arrest and Selected Life-Threatening Medical Emergencies, Mary Fran Hazinski; et al, American Heart Association, September 16, 2016
[2] Model M5066A
[3] Model M5068A
[4] Battery Model M5070A. SMART Pads Cartridges Models M5071A and M5072A
For further information, please contact:
Joost Maltha
Philips Group Press Office
Tel. : +31 6 10 55 8116
E-mail : joost.maltha@philips.com
Twitter: @joostmaltha
Kathy O’Reilly
Philips Group Press Office
Tel. : +1 978-221-8919
E-mail : kathy.oreilly@philips.com
Twitter: @kathyoreilly
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2018 sales of EUR 18.1 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
Source: Philips International B.V. via GLOBE NEWSWIRE
